Skip to main content
Top

25-04-2024 | Breast Cancer | Clinical trial

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey

Authors: M. Bradbury, MF Savard, C. Stober, L. Clemons, M. Clemons, J. Hilton, G. Pond, L. Vandermeer, SF McGee

Published in: Breast Cancer Research and Treatment

Login to get access

Abstract

Purpose

Despite previous studies proposing shorter durations of anti-HER2 therapy for selected patients with HER2-positive early breast cancer (EBC), 12-months remains standard of care. A survey was performed to assess patient perspectives and willingness to participate in studies evaluating shorter durations of anti-HER2 therapy.

Methods

Patients with HER2-positive EBC completing or having previously completed anti-HER2 therapy, were recruited by healthcare professionals at The Ottawa Hospital Cancer Centre to participate in an anonymous online survey. The primary objective was to learn about patients’ perspectives on shorter durations (less than 12-months) of anti-HER2 therapy. Secondary objectives were to explore patients’ interest in clinical trials of shorter durations of anti-HER2 therapy and the degree of increased breast cancer risk they would accept with a shorter treatment duration.

Results

Responses were received from 94 eligible patients. Most patients received Trastuzumab alone (78%, 73/94), while 13% (12/94) received trastuzumab and pertuzumab. Side effects were experienced by 52% (46/89), the most common being; fatigue (61%, 28/46), myalgia (37%, 17/46), and diarrhea (24%, 11/46). Most patients (88%, 78/89) did not find treatment bothersome. Regarding perspectives on shorter durations of anti-HER2 therapy, most (79%, 74/94) respondents stated they would agree to less treatment if it were possible to receive fewer treatments with the same cancer benefits. 56% of patients were interested in clinical trials, however, about half stated they would not be accepting of any increase in breast cancer recurrence risk.

Conclusion

Trials to investigate who can safely and effectively be treated with shorter durations of anti-HER2 therapy are needed. This study provides important insights to patients’ perspectives on shorter durations of anti-HER2 treatment, and their concerns regarding potential increased cancer risk with less treatment.
Appendix
Available only for authorised users
Literature
8.
go back to reference Mavroudis D, Saloustros E, Malamos N, Kakolyris S, study by the Hellenic Oncology Research Group (HORG) Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized - Annals of Oncology. Accessed: Nov. 07, 2022. [Online]. Available: https://www.annalsofoncology.org/article/S09237534(19)34520-X/fulltext Mavroudis D, Saloustros E, Malamos N, Kakolyris S, study by the Hellenic Oncology Research Group (HORG) Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized - Annals of Oncology. Accessed: Nov. 07, 2022. [Online]. Available: https://​www.​annalsofoncology​.​org/​article/​S09237534(19)34520-X/fulltext
9.
go back to reference Earl HM et al (2019) Jun., 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial, Lancet Lond. Engl, vol. 393, no. 10191, pp. 2599–2612, https://doi.org/10.1016/S0140-6736(19)30650-6 Earl HM et al (2019) Jun., 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial, Lancet Lond. Engl, vol. 393, no. 10191, pp. 2599–2612, https://​doi.​org/​10.​1016/​S0140-6736(19)30650-6
11.
go back to reference Conte P, Guarneri V, Bisagni G, Piacentini F, Brandes AA et al (2018) Congress 9 weeks versus 1 year adjuvant trastuzumab for HER2 + early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio, presented at the ESMO 2018 Conte P, Guarneri V, Bisagni G, Piacentini F, Brandes AA et al (2018) Congress 9 weeks versus 1 year adjuvant trastuzumab for HER2 + early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio, presented at the ESMO 2018
13.
go back to reference NCCN (2023) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2023. Mar. 23 NCCN (2023) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2023. Mar. 23
19.
go back to reference Earl HM, Hiller L, Dunn JA, Conte P, D’Amico R et al (2021) LBA11 - Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer, presented at the ESMO Congress, 2021 Earl HM, Hiller L, Dunn JA, Conte P, D’Amico R et al (2021) LBA11 - Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer, presented at the ESMO Congress, 2021
21.
Metadata
Title
Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey
Authors
M. Bradbury
MF Savard
C. Stober
L. Clemons
M. Clemons
J. Hilton
G. Pond
L. Vandermeer
SF McGee
Publication date
25-04-2024
Publisher
Springer US
Published in
Breast Cancer Research and Treatment
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-024-07302-0
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare